• Featured Product
  • KD/KO Validated

KMT2D Polyclonal antibody

KMT2D Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human and More (1)

Applications

WB, IHC, IF, ChIP, ELISA

Conjugate

Unconjugated

Cat no : 27266-1-AP

Synonyms

MLL2, KMT2D/MLL2



Tested Applications

Positive WB detected inHEK-293 cells
Positive IHC detected inhuman breast cancer tissue, human lymphoma tissue, human colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:2000-1:16000
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

27266-1-AP targets KMT2D in WB, IHC, IF, ChIP, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen KMT2D fusion protein Ag26195
Full Name myeloid/lymphoid or mixed-lineage leukemia 2
Calculated Molecular Weight 593 kDa
Observed Molecular Weight593 kDa
GenBank Accession NumberNM_003482
Gene Symbol KMT2D/MLL2
Gene ID (NCBI) 8085
RRIDAB_2880823
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

KMT2D (a COMPASS/ Set1 family member; also known as MLL4, ALR, and MLL2) is the biggest H3K4 methyltransferase among the most frequently mutated genes in many different types of cancer (PMID: 34194626). The enzymatic function of KMT2D depends on a cluster of C-terminal conserved domains, including a PHD domain, two FY-rich motifs (FYRC and FYRN) and a catalytic SET domain. KMT2D has two frequently occurring genomic alterations: truncation and missense mutations. Loss of KMT2D is a bona fide tumor suppressor gene in FL and DLBCL. Kmt2d perturbed the expression of genes that sustain proliferation and survival, and the KMT2D protein directly binds and associates with an active chromatin conformation in negative modulators of the BCR and lymphocyte migration pathways, which in turn could affect B cell responses to antigen(PMID: 26366712).

Protocols

Product Specific Protocols
WB protocol for KMT2D antibody 27266-1-APDownload protocol
IHC protocol for KMT2D antibody 27266-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Cancer Immunol Res

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis.

Authors - Xuanwen Bao
humanIHC

Oncogene

Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.

Authors - Xuejiao Leng
humanIHC,IF

Cell Biosci

Histone methyltransferase KMT2D cooperates with MEF2A to promote the stem-like properties of oral squamous cell carcinoma.

Authors - Xinmiao Wang
humanIHC

Thorac Cancer

RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.

Authors - Ning Jiang
humanWB,IHC

Transl Cancer Res

Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer

Authors - Qiliang Zhai
ChIP

Cell Death Discov

Pseudogene ACTBP2 increases blood-brain barrier permeability by promoting KHDRBS2 transcription through recruitment of KMT2D/WDR5 in Aβ1-42 microenvironment.

Authors - Qianshuo Liu